Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of migraines (with or without aura) for ≥ 12 months~* Migraine frequency: ≥ 4 and \< 15 migraine days per month on average acrossthe 3 months prior to screening~* Headache (ie, migraine and non-migraine headache) frequency: \< 15 headache days per month on average across the 3 months prior to screening~* Demonstrated compliance with the eDiary~Exclusion Criteria:~* Older than 50 years of age at migraine onset.~* History of cluster headache or hemiplegic migraine headache.~* Unable to differentiate migraine from other headaches~* No therapeutic response with \> 2 categories for prophylactic treatment of migraine after an adequate therapeutic trial.~* Concomitant use of 2 or more medications with possible migraine prophylactic effects within 2 months prior to the start of the baseline phase or during the baseline phase. If only 1 prophylactic medication is used, the dose must be stable within 2 months prior to the start of the baseline phase and throughout the study~* Used a prohibited medication, device, or procedure within 2 months prior to the start of the baseline phase or during the baseline phase.~* Received botulinum toxin~* Anticipated to require any excluded medication, device, or procedure during the study.~* Active chronic pain syndromes (such as fibromyalgia and chronic pelvic pain).~* History of major psychiatric disorder.~* History of seizure disorder or other significant neurological conditions other than migraine.~* Human immunodeficiency virus (HIV) infection by history.~* Myocardial infarction (MI), stroke, transient ischemic attack (TIA), unstable angina, or coronary artery bypass surgery or other revascularization procedure within 12 months prior to screening.~* The subject is at risk of self-harm or harm to others. Previously randomized into an AMG 334 study.~* Unlikely to be able to complete all protocol required study visits or procedures, and/or to comply with all required study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. At week 12 participants began treatment with erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
- Erenumab (Type: EXPERIMENTAL): Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. Participants continued to receive erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).